Breathe Well Live Well
|
Biopharma raising $500K eyes competitive asthma/COPD drug market
MedCity News A biopharmaceutical startup developing a new treatment for asthma that targets the nitric oxide signaling system has raised $50000 of a planned $500000 fundraise, according to recently filed SEC documents. SAJE Pharma LLC's lead compound appears to … |
View full post on asthma – Google News
|
Recent Asthma Findings Could Open a New Market for ChromaDex (CDXC)
SmallCap Network The findings, which were published in the Journal of Agricultural and Food Chemistry, showed that pterostilbene may counteract the role of environmental pollutants and prevent the development of asthma. Pterostilbene is a compound found in blueberries. |
View full post on asthma – Google News
 mobihealthnews |
iSonea rapidly approaches commercialisation, targets US$16 billion asthma market
Proactive Investors USA & Canada iSonea (ASX: ISN) is preparing to roll out a number of its asthma products over the next 24 months after entering its first formal partnership with telecommunications company Qualcomm Life for the development of a mobile asthma monitoring platform. iSonea to Develop New Asthma Mobile Health Technology Based on Qualcomm 2net Hub Qualcomm Life, iSonea to offer mobile asthma monitor iSonea gains partner to develop new mobile asthma monitoring system |
View full post on asthma – Google News
mobihealthnews |
iSonea rapidly approaches commercialisation, targets US$16 billion asthma market
Proactive Investors UK iSonea (ASX: ISN) is preparing to roll out a number of its asthma products over the next 24 months after entering its first formal partnership with telecommunications company Qualcomm Life for the development of a mobile asthma monitoring platform. iSonea to Develop New Asthma Mobile Health Technology Based on Qualcomm 2net Hub Qualcomm Life, iSonea to offer mobile asthma monitor iSonea gains partner to develop new mobile asthma monitoring system |
View full post on asthma – Google News
 Los Angeles Times |
Asthmatics' options now that Primatene Mist is off the market
Los Angeles Times Asthma sufferers can use inhalers with non-CFC chemical propellants, available through health centers for those who cannot afford a doctor's care or insurance. Primatene Mist, a nonprescription inhaler used to help asthma patients breathe better during … |
View full post on asthma – Google News
 Proactive Investors Australia |
iSonea launches into US market with American Depositary Receipts
Proactive Investors Australia Medical technology company iSonea is focused on developing innovative monitoring systems and software for the management of asthma. The company is currently working on the development and launch of the first Acoustic Respiratory Monitoring devices, … iSonea rights issues provides better than expected return of A$4.6m |
View full post on asthma – Google News
|
Over-the-counter inhalers taken off the market
NBC2 News By Joelle Parks, NBC2 Reporter – email Local pharmacies are preparing to take the only over-the-counter asthma inhaler off the shelves. It's because of concerns it's propellant is damaging the ozone layer. For Katie Carsi's daughter, her inhaler is a … |
View full post on asthma – Google News
|
Pfizer wins right to challenge Prempro damages award; Asthma market flat until …
FiercePharma Item > The asthma drug market will remain flat at around $14.4 billion through 2020, thanks in part to generic rivals for Merck's ($MRK)Singulair, Decision Resources concludes. Release > Teva Pharmaceutical Industries ($TEVA) won an appeals court's … |
View full post on asthma – Google News
|
Through 2020, the Asthma Drug Market Will Remain Flat Amidst Generic Erosion …
BioMedReports (subscription) The overall asthma drug market will decrease slightly from $14.6 billion in 2010 to $14.4 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. “Driving these sales will be the uptake of emerging once-daily … Through 2020, the Asthma Drug Market Will Remain Flat Amidst Generic Erosion … |
View full post on asthma – Google News
|
Through 2020, the Asthma Drug Market Will Remain Flat Amidst Generic Erosion …
MarketWatch (press release) The overall asthma drug market will decrease slightly from $14.6 billion in 2010 to $14.4 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The Pharmacor advisory service entitled Asthma finds that the … |
View full post on asthma – Google News